Roche Venture Fund and Amgen will invest in the stem cell-transplant technology developer through a reverse merger transaction which will give it a $490m market capitalisation.
Jasper Therapeutics, a US-based stem cell-transplant technology developer backed by pharmaceutical firm Roche, has agreed to a reverse merger with special purpose acquisition company (SPAC) Amplitude Healthcare Acquisition Corp.
The company will acquire the listing on the Nasdaq Capital Market obtained by Amplitude in a $100m initial public offering in November 2019. The deal will grant the merged company an initial market capitalisation of approximately $490m.
The reverse merger deal is backed by $100m private investment in public equity (PIPE)…
